Overview
ISO/HL7 27953-2:2011 establishes a harmonized framework for electronic Individual Case Safety Reports (ICSRs) in pharmacovigilance for human pharmaceutical reporting. Developed jointly by ISO and HL7, Part 2 of the 27953 series defines a common set of data elements and a messaging format to support international regulatory reporting and secure information sharing of adverse drug reactions (ADR), adverse events (AE), infections and other incidents related to the administration of one or more human medicinal products.
This standard facilitates consistent capture and transmission of safety case information regardless of source or destination, improving interoperability between healthcare providers, manufacturers, national competent authorities and global safety databases.
Key Topics and Requirements
- Common data model: A standardized set of ICSR data elements to represent cases consistently across organizations and jurisdictions.
- Messaging format: Definitions for electronic transmission of ICSRs to enable automated exchange between systems.
- Coverage: Reporting requirements applicable to ADRs, AEs, infections and related incidents involving human pharmaceutical products.
- Interoperability focus: Alignment with health informatics practices to support integration with clinical systems, safety databases and regulatory workflows.
- Regulatory reporting orientation: Enables submission-ready ICSR content to meet national and international pharmacovigilance obligations.
Note: ISO/HL7 27953-2 specifies the structure and content scope for ICSR exchanges rather than prescribing a particular software implementation.
Practical Applications and Users
Who uses ISO/HL7 27953-2:
- Pharmacovigilance teams in pharmaceutical companies for preparing and transmitting standardized ICSRs.
- Regulatory authorities and public health agencies for intake, review and cross-jurisdictional exchange of safety reports.
- Health IT vendors and EHR/EPR system integrators implementing electronic ADR/AE reporting modules.
- Hospitals, clinics and clinical trial sponsors that need to report safety events in a compliant, machine-readable format.
Practical benefits:
- Reduces ambiguity and manual rework in safety reporting.
- Streamlines automated ingestion of case reports into signal detection and case management systems.
- Improves timeliness and quality of data exchanged between manufacturers, regulators and care providers.
Related Standards
- Other parts of the ISO/HL7 27953 series (ICSR architecture and related guidance).
- HL7-related implementation frameworks and clinical data exchange standards used in safety-reporting workflows.
Keywords: ISO/HL7 27953-2, ICSR, pharmacovigilance standard, adverse drug reaction reporting, electronic safety report, ADR reporting, human pharmaceutical reporting.
